title: Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
abstract: BACKGROUND
  Oclacitinib is safe and effective for treating dogs with pruritus associated with allergic and atopic dermatitis, based on randomized clinical trials of up to 4 months duration.
  
  
  OBJECTIVE
  This study assessed long-term safety, efficacy and quality of life of oclacitinib-treated dogs enrolled in a compassionate use programme.
  
  
  METHODS
  Two hundred and forty-seven client-owned dogs with allergic skin disease that had previously benefited from oclacitinib therapy.
  
  
  METHODS
  Dogs were enrolled in an open-label study at 26 veterinary clinics. Dogs received 0.4-0.6 mg/kg oclacitinib twice a day for 14 days, then once a day for up to 630 days. Assessments were performed at ~90 day intervals. Owners completed a quality-of-life survey and assessed pruritus using a Visual Analog Scale (VAS) at each clinic visit. Veterinarians assessed dermatitis using a similar VAS. Abnormal health events, concomitant medication and clinical pathology results were summarized.
  
  
  RESULTS
  Visual Analog Scale scores showed improvement from baseline at all time points. The percentage of dogs showing ≥50% reduction from baseline on day 90 was 63.9% for pruritus and 66.4% for dermatitis. Owners saw a positive impact on quality of life in >91% of all dogs. Urinary tract infection/cystitis, vomiting, otitis, pyoderma and diarrhoea were the most frequently reported (>5% of dogs) abnormal clinical signs. Haematology and serum chemistry means remained within the normal reference ranges. Concomitant medications were well tolerated.
  
  
  CONCLUSIONS
  Results indicated that oclacitinib was safe and efficacious for long-term use and improved the quality of life for dogs in this study.
authors: Zoetis Inc., Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
authors: Sallie B
authors: SB
authors: Cosgrove
authors: Zoetis Inc., Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
authors: Dawn M
authors: DM
authors: Cleaver
authors: Zoetis Inc., Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
authors: Vickie L
authors: VL
authors: King
authors: Zoetis Inc., Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
authors: Amy R
authors: AR
authors: Gilmer
authors: Zoetis Inc., Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
authors: Anne E
authors: AE
authors: Daniels
authors: Zoetis Inc., Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
authors: Jody A
authors: JA
authors: Wren
authors: Zoetis Inc., Veterinary Medicine Research and Development, Mercuriusstraat 20, Zaventem, B-1930, Belgium.
authors: Michael R
authors: MR
authors: Stegemann
mesh_terms: D000818:Animals; D057176:Compassionate Use Trials / Q000662:veterinary; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy / Q000662:veterinary*; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000662:veterinary*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004334:Drug Administration Schedule / Q000662:veterinary; D005260:Female; D008297:Male; D011537:Pruritus / Q000188:drug therapy / Q000662:veterinary*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D064232:Visual Analog Scale
chemical_list: D003879:Dermatologic Agents; D011743:Pyrimidines; D013449:Sulfonamides; C588062:oclacitinib